KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $3.0 billion.

  • Biogen's Cash & Equivalents rose 2667.37% to $3.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.0 billion, marking a year-over-year increase of 2667.37%. This contributed to the annual value of $3.0 billion for FY2025, which is 2667.37% up from last year.
  • According to the latest figures from Q4 2025, Biogen's Cash & Equivalents is $3.0 billion, which was up 2667.37% from $3.9 billion recorded in Q3 2025.
  • In the past 5 years, Biogen's Cash & Equivalents registered a high of $3.9 billion during Q3 2025, and its lowest value of $1.0 billion during Q4 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $2.3 billion (2023), whereas its average is $2.3 billion.
  • As far as peak fluctuations go, Biogen's Cash & Equivalents crashed by 6929.49% in 2023, and later surged by 14183.73% in 2025.
  • Biogen's Cash & Equivalents (Quarter) stood at $2.3 billion in 2021, then surged by 51.2% to $3.4 billion in 2022, then plummeted by 69.29% to $1.0 billion in 2023, then soared by 126.21% to $2.4 billion in 2024, then grew by 26.67% to $3.0 billion in 2025.
  • Its Cash & Equivalents stands at $3.0 billion for Q4 2025, versus $3.9 billion for Q3 2025 and $2.8 billion for Q2 2025.